Abstract
Francisella tularensis is a small Gram-negative aerobic intracellular bacterium that should be considered as a possible pathogen in patients with fever, pharyngitis, and lymphadenopathia. Central nervous system manifestations have been rarely reported. We describe a patient who developed serious Guillain–Barré polyneuropathy as a rare complication of ulceroglandular tularemia.
References
National Public Health Institution. Infectious diseases register. 2012. http://www.thl.fi.
Snowden J, Stovall S. Tularemia: retrospective review of 10 years’ experience in Arkansas. Clin Pediatr. 2011;50:64–8.
Thomas LD, Schaffner W. Tularemia pneumonia. Infect Dis Clin North Am. 2010;24:43–55.
Foley JE, Nieto NC. Tularemia. Vet Microbiol. 2010;140:332–8.
Ulu-Kilic A, Gulen G, Sezen F, Kilic S, Sencan I. Tularemia in central Anatolia. Infection. 2013;41:391–9.
Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States. Arch Neurol. 2009;66:523–7.
Gangat N. Cerebral abscesses complicating tularemia meningitis. Scand J Infect Dis. 2007;39:258–61.
van de Beek D, Steckelberg JM, Marshall WF, Kijpittayarit S, Wijdicks EFM. Tularemia with brain abscesses. Neurology. 2007;68:531.
Syrjälä H, Koskela P, Kujala P, Myllylä V. Guillain–Barré syndrome and tularemia pleuritis with high adenosine deaminase activity in pleural fluid. Infection. 1989;17:152–3.
Sutinen S, Syrjälä H. Histopathology of human lymph node tularemia caused by Francisella tularensis var palaearctica. Arch Pathol Lab Med. 1986;110:42–6.
Syrjälä H, Schildt R, Räisäinen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur J Clin Microbiol Infect Dis. 1991;10:68–70.
Ikäheimo I, Syrjälä H, Karhukorpi J, Schildt R, Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. J Antimicrob Chemother. 2000;46:287–90.
van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain–Barré syndrome. J Clin Microbiol. 2010;30:S74–8.
Contentin L, Soret J, Zamfir O, Gontier O, Lherm T, Hamrouni M, Ouchenir A, Monchamps G, Kalfon P. Francisella tularensis meningitis. Med Mal Infect. 2011;41:556–8.
Hughes RAC, Swan AV, Raphaël JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain–Barré syndrome: a systematic review. Brain. 2007;130:2245–57.
Rajabally YA. Treatment of Guillain–Barré syndrome: a review. Inflamm Allergy Drug Targets. 2012;11:330–4.
Yuki N, Hartung HP. Guillain–Barré syndrome. N Engl J Med. 2012;366:2294–304.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ylipalosaari, P., Ala-Kokko, T.I., Tuominen, H. et al. Guillain–Barré syndrome and ulceroglandular tularemia. Infection 41, 881–883 (2013). https://doi.org/10.1007/s15010-013-0466-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-013-0466-3